Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effects of Mirtazapine Versus Placebo on Alcohol Consumption in Male Alcohol High Consumers

This study has been completed.
Sponsor:
Information provided by:
Sahlgrenska University Hospital, Sweden
ClinicalTrials.gov Identifier:
NCT00874003
First received: April 1, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted
  Purpose

The purpose of this study is to study the effects of 8 weeks of treatment with mirtazapine on alcohol consumption in alcohol high consuming men. This study is a randomized, double-blind placebo controlled clinical trial with parallel group design(N=59).


Condition Intervention Phase
Alcohol Dependence
Drug: mirtazapine
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effects of Mirtazapine vs Placebo on Alcohol Consumption in Male Alcohol High Consumers; a Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Sahlgrenska University Hospital, Sweden:

Primary Outcome Measures:
  • Alcohol consumption measured by alcohol diary (units/week). [ Designated as safety issue: No ]

Enrollment: 59
Study Start Date: April 2004
Study Completion Date: February 2009
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: mirtazapine, tablet, 30 mg
n=29
Drug: mirtazapine
oral tablet, 30 mg daily
Placebo Comparator: sugar pill
n=30
Drug: placebo
oral tablet, 1 daily

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18-65 years of age
  • male sex
  • alcohol high consumption
  • signed informed consent

Exclusion Criteria:

  • psychiatric disorders (except nicotine and alcohol dependence)
  • severe somatic disorders
  • inadequate knowledge of the Swedish language
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00874003

Locations
Sweden
Addiction Biology Unit
Gothenburg, Sweden, 413 45
Sponsors and Collaborators
Sahlgrenska University Hospital, Sweden
Investigators
Study Director: Andrea deBejczy, MD Addiction Biology Unit
Principal Investigator: Bo Söderpalm, MD, PhD Addiction Biology Unit
  More Information

No publications provided

Responsible Party: Bo Söderpalm/ MD, PhD, sponsor, Addiction Biology Unit, Sahlgrenska University Hospital, Sweden
ClinicalTrials.gov Identifier: NCT00874003     History of Changes
Other Study ID Numbers: GOTABU-BO1
Study First Received: April 1, 2009
Last Updated: April 1, 2009
Health Authority: Sweden: Medical Products Agency

Keywords provided by Sahlgrenska University Hospital, Sweden:
alcohol dependence
anti-depressant
5-HT
NE

Additional relevant MeSH terms:
Alcohol Drinking
Alcoholism
Alcohol-Related Disorders
Chemically-Induced Disorders
Drinking Behavior
Mental Disorders
Substance-Related Disorders
Mirtazapine
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-Antagonists
Antidepressive Agents
Antidepressive Agents, Tricyclic
Central Nervous System Agents
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014